Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
World Journal of Surgical Oncology
Published in: World Journal of Surgical Oncology 1/2018

Open Access 01-12-2018 | Research

Outcome and prognostic factors in cervical cancer patients treated with surgery and concurrent chemoradiotherapy: a retrospective study

Authors: Yan-Mei Liu, Ling-Qin Ni, Sai-Sai Wang, Qian-Ling Lv, Wei-Jun Chen, Shen-Peng Ying

Published in: World Journal of Surgical Oncology | Issue 1/2018

Login to get access

Abstract

Background

The objective of this study is to analyze the treatment outcome and secondary reactions in 98 patients with stage I–III cervical carcinoma who underwent postoperative radiotherapy.

Methods

From 2006 to 2014, 98 patients with stage I–III cervical carcinoma were treated with postoperative radiotherapy. The major histological type, found in 92.86% of the patients (91 cases), was squamous cell carcinoma. Patients were staged according to the 2002 TNM guidelines. The postoperative radiotherapy methods included two-field irradiation (16 patients, 16.32%), four-field box irradiation (16 patients, 16.32%), and intensity-modulated radiotherapy (IMRT; 66 patients, 67.36%). The survival rates were represented using Kaplan-Meier curves, and prognosis analyses were performed using Cox multivariate analyses.

Results

The 5-year overall survival and progression-free survival rates were 82.0 and 76.0%, respectively. Only one patient (1.02%) developed a grade 3 acute radiation enteritis, while grade 3 and 4 myelosuppression was noted in 17 patients (17.35%) and one patient (1.02%), respectively. Multivariate analyses showed that anemia before radiotherapy and tumor size were predictors of the OS (P = 0.008, P = 0.045) rates.

Conclusions

Postoperative radiotherapy for patients with risk factors of cervical cancer procured good efficacy levels with mild side effects. Anemia and tumor size were important OS predictors.
Literature
1.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRefPubMed
2.
J. Ferlay, I. Soerjomataram, R. Dikshit, et al.Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012, Int. J.Cancer 136 (2015) E359-E386.
3.
Ohara K, Sugahara S, Kagei K, Hata M, Igaki H, Tokuuye K, et al. Retrospective comparison of clinical outcome between radiotherapy alone and surgery plus postoperative radiotherapy in the treatment of stages IB-IIB cervical squamous cell carcinoma. Radiat Med. 2004;22:42–8.PubMed
4.
Peters WA 3rd, Liu PY, Barrett RJ 2nd, Stock RJ, Monk BJ, Berek JS, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol. 2000;18:1606–13.CrossRefPubMed
5.
Landoni F, Maneo A, Colombo A, Placa F, Milani R, Perego P, et al. Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer. Lancet. 1997;350:535–40.CrossRefPubMed
6.
Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995;31:1341–6.CrossRefPubMed
7.
Boyce J, Fruchter RG, Nicastri AD, Ambiavagar PC, Reinis MS, Nelson JH. Prognostic factors in stage I carcinoma of the cervix. Gynecol Oncol. 1981;12:154–65.CrossRefPubMed
8.
Delgado G, Bundy B, Zaino R, Sevin BU, Creasman WT, Major F. Prospective surgical pathological study of disease-free interval in patients with stage IB squamous cell carcinoma of the cervix: a gynecologic oncology group study. Gynecol Oncol. 1990;38:352–7.CrossRefPubMed
9.
Fuller AF Jr, Elliott N, Kosloff C, Hoskins WJ, Lewis JL. Determinants of increased risk for recurrence in patients undergoing radical hysterectomy for stage IB and IIA carcinoma of the cervix. Gynecol Oncol. 1989;33:34–9.CrossRefPubMed
10.
Chung CK, Nahhas WA, Stryker JA, Curry SL, Abt AB, Mortel R. Analysis of factors contributing to treatment failures in stages IB and IIA carcinoma of the cervix. Am J Obstet Gynecol. 1980;138:550–6.CrossRefPubMed
11.
Samlal RA, van der Velden J, Schilthuis MS, González González D, Ten Kate FJ, et al. Identification of high-risk groups among node-positive patients with stage IB and IIA cervical carcinoma. Gynecol Oncol. 1997;64:463–7.CrossRefPubMed
12.
Rotman M, Sedlis A, Piedmonte MR, Bundy B, Lentz SS, Muderspach L, et al. A phase III randomized trial of postoperative pelvic irradiation in stage IB cervical carcinoma with poor prognostic features:follow-up of a gynecologic oncology group study. Int J Radiat Oncol Biol Phys. 2006;65:169–76.CrossRefPubMed
13.
Song S, Song C, Kim HJ, HG W, Kim JH, Park NH, et al. 20 year experience of postoperative radiotherapy in IB-IIA cervical cancer patients with intermediate risk factors: impact of treatment period and concurrent chemotherapy. Gynecol Oncol. 2012;124:63–7.CrossRefPubMed
14.
Pearcey R, Miao Q, Kong W, Zhang SJ, Mackillop WJ. Impact of adoption of chemoradiotherapy on the outcome of cervical cancer in Ontario: results of a population based cohort study. J Clin Oncol. 2007;25:2383–8.CrossRefPubMed
15.
Chemoradiotherapy for Cervical Cancer Meta-Analysis Collaboration. Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials. J Clin Oncol. 2008;26:5802–12.CrossRefPubMedCentral
16.
Choi IJ, Cha MS, Park ES, Han MS, Choi Y, Je GH, et al. The efficacy of concurrent cisplatin and 5-flurouracil chemotherapy and radiation therapy for locally advanced cancer of the uterine cervix. J Gynecol Oncol. 2008;19:129–34.CrossRefPubMedPubMedCentral
17.
Wang J, Wang T, Yang YY, Chai YL, Shi F, Liu ZI. Patient age, tumor appearance and tumor size are risk factors for early recurrence of cervical cancer. Mol Clin Oncol. 2015;3:363–6.CrossRefPubMed
18.
Kastritis E, Bamias A, Bozas G, Koutsoukou V, Voulgaris Z, Vlahos G, et al. The impact of age in the outcome of patients with advanced or recurrent cervical cancer after platinum-based chemotherapy. Gynecol Oncol. 2007;104:372–6.CrossRefPubMed
19.
Kasuya G, Ogawa K, Iraha S, Nagai Y, Hirakawa M, Toita T, et al. Postoperative radiotherapy for uterine cervical cancer: impact of lymph node and histological type on survival. Anticancer Res. 2013;33:2199–204.PubMed
20.
Okazawa M, Mabuchi S, Isohashi F, Suzuki O, Yoshioka Y, Sasano T, et al. Impact of the addition of concurrent chemotherapy to pelvic radiotherapy in surgically treated stage IB1-IIB cervical cancer patients with intermediate-risk or high-risk factors: a 13-year experience. Int J Gynecol Cancer. 2013;23(3):567–75.CrossRefPubMed
21.
Eifel PJ, Jhingran A, Levenback CF, Tucker S. Predictive value of a proposed subclassification of stages I and II cervical cancer based on clinical tumor diameter. Int J Gynecol Cancer. 2009;19:2–7.CrossRefPubMed
22.
Cho HC, Kim H, Cho HY, Kim K, No JH, Kim YB. Prognostic significance of perineural invasion in cervical cancer. Int J Gynecol Pathol. 2013;32:228–33.CrossRefPubMed
23.
Lee DW, Kim YT, Kim JH, Kim S, Kim SW, Nam EJ. Clinical significance of tumor volume and lymph node involvement assessed by MRI in stage IIB cervical cancer patients treated with concurrent chemoradiation therapy. J Gynecol Oncol. 2010;21:18–23.CrossRefPubMedPubMedCentral
24.
Wakayama A, Inamine M, Kudaka W, Nagai Y, Nakamoto T, Ooyama T, et al. Concurrent chemoradiotherapy for non-bulky stage IB/II cervical cancer without pelvic node enlargement. Anticancer Res. 2013;33:5123–6.PubMed
25.
Lee HN, Mahajan MK, Das S, Sachdeva J, Tiwana MS. Early hematological effects of chemo-radiation therapy in cancer patients and their pattern of recovery—a prospective single institution study. Gulf J Oncolog. 2015;1:43–51.PubMed
26.
Bishop AJ, Allen PK, Klopp AH, Meyer LA, Eifel PJ, et al. Relationship between low hemoglobin levels and outcomes after treatment with radiation or chemoradiation in patients with cervical cancer: has the impact of anemia been overstated? Int J Radiat Oncol Biol Phys. 2015;91:196–205.CrossRefPubMed
27.
Barter JF, Soong SJ, Hatch KD, Orr JW, Shingleton HM. Diagnosis and treatment of pulmonary metastases from cervical carcinoma. Gynecol Oncol. 1990;38:347–51.CrossRefPubMed
28.
Ki EY, Lee KH, Park JS, Hur SY. A clinicopathological review of pulmonary metastasis from uterine cervical cancer. Cancer Res Treat. 2016;48:66–72.CrossRef
29.
Agrawal A, Kumar A, Sinha AK, Kumar M, Pandey SR, Khaniya S. Intracranial metastases from carcinoma of the cervix. Singap Med J. 2007;48:154–6.
30.
Chura JC, Shukla K, Argenta PA. Brain metastasis from cervical carcinoma. Int J Gynecol Cancer. 2007;17:141–6.CrossRefPubMed
31.
Sato Y, Tanaka K, Kobayashi Y, Shibuya H, Nishigaya Y, Momomura M, et al. Uterine cervical cancer with brain metastasis as the initial site of presentation. J Obstet Gynaecol Res. 2015;41:1145–8.CrossRefPubMed
32.
Hwang JH, Yoo HJ, Lim MC, Seo SS, Kang S, Kim JY, et al. Brain metastasis in patients with uterine cervical cancer. J Obstet Gynaecol Res. 2013;39:287–91.CrossRefPubMed
33.
Pu J, Qin SS, Ding JX, Zhang YZ, Wei G, Yu CH, et al. A randomized controlled study of single-agent cisplatin and radiotherapy versus docetaxel/cisplatin and radiotherapy in high-risk early-stage cervical cancer after radical surgery. J Cancer Res Clin Oncol. 2013;139:703–8.CrossRefPubMed
Metadata
Title
Outcome and prognostic factors in cervical cancer patients treated with surgery and concurrent chemoradiotherapy: a retrospective study
Authors
Yan-Mei Liu
Ling-Qin Ni
Sai-Sai Wang
Qian-Ling Lv
Wei-Jun Chen
Shen-Peng Ying
Publication date
01-12-2018
Publisher
BioMed Central
Published in
World Journal of Surgical Oncology / Issue 1/2018
Electronic ISSN: 1477-7819
DOI
https://doi.org/10.1186/s12957-017-1307-0

Other articles of this Issue 1/2018

World Journal of Surgical Oncology 1/2018 Go to the issue

Research

Mesh-reinforced pancreaticojejunostomy versus conventional pancreaticojejunostomy after pancreaticoduodenectomy: a retrospective study of 126 patients

Case report

Case report: synovial sarcoma of the axilla with brachial plexus involvement

Research

Malignant adnexal tumors of the skin: a single institution experience

Research

Evaluation of the HOXA11 level in patients with lung squamous cancer and insights into potential molecular pathways via bioinformatics analysis

Research

Long-term oncologic outcomes of radiotherapy combined with maximal androgen blockade for localized, high-risk prostate cancer

Research

Diffusion-weighted imaging in monitoring the pathological response to neoadjuvant chemotherapy in patients with breast cancer: a meta-analysis